公开(公告)号：US20240325410A1

公开(公告)日：2024-10-03

申请号：US18386447

申请日：2023-11-02

申请人： The Brain Health Project, LLC

发明人： Morris Notelovitz

IPC分类号： A61K31/593 ,  A23L33/10 ,  A61K31/353 ,  A61K31/4748 ,  A61K31/566 ,  A61K31/592 ,  G01N33/68

CPC分类号： A61K31/593 ,  A23L33/10 ,  A61K31/353 ,  A61K31/4748 ,  A61K31/566 ,  A61K31/592 ,  G01N33/6896 ,  A23V2002/00 ,  A61K2300/00 ,  G01N2800/28 ,  G01N2800/52

摘要： The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.

公开(公告)号：US11752158B2

公开(公告)日：2023-09-12

申请号：US12597230

申请日：2008-04-25

申请人： P. Martin Petkovich ,  Christian F. Helvig ,  Samir P. Tabash

发明人： P. Martin Petkovich ,  Christian F. Helvig ,  Samir P. Tabash

IPC分类号： A61K31/592 ,  A61K31/593

CPC分类号： A61K31/592 ,  A61K31/593

摘要： The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.

公开(公告)号：US11730760B2

公开(公告)日：2023-08-22

申请号：US14937858

申请日：2015-11-10

申请人： BIOREGENTECH, INC.

发明人： Margaret Kalmeta

IPC分类号： A61K33/42 ,  A61K31/198 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/401 ,  A61K31/7076 ,  A61K31/221 ,  A61K31/7072 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/192 ,  A61K33/14 ,  A61K31/7048 ,  A61K31/7004 ,  A61K31/7008 ,  A61K31/07 ,  A61K31/592 ,  A61K31/593 ,  A61K31/355 ,  A61K31/122 ,  A61K31/714 ,  A61K31/575 ,  A61K31/51 ,  A61K31/525 ,  A61K31/455 ,  A61K31/197 ,  A61K31/675 ,  A61K31/4188 ,  A61K31/519 ,  A61K31/375 ,  A61K31/14 ,  A61K33/06 ,  A61K33/00 ,  A61K33/18 ,  A61K33/24 ,  A61K33/38 ,  A61K33/34 ,  A61K33/30 ,  A61K33/04 ,  A61K33/26 ,  A61K33/22 ,  A61K8/368 ,  A61K8/24 ,  A61K8/44 ,  A61K8/20 ,  A61K8/60 ,  A61Q11/00 ,  A61N5/06 ,  A61C1/00 ,  A61K8/41 ,  A61K33/242 ,  A61N5/067

CPC分类号： A61K33/42 ,  A61C1/0046 ,  A61K8/20 ,  A61K8/24 ,  A61K8/368 ,  A61K8/416 ,  A61K8/44 ,  A61K8/442 ,  A61K8/606 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/192 ,  A61K31/197 ,  A61K31/198 ,  A61K31/221 ,  A61K31/355 ,  A61K31/375 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4188 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/575 ,  A61K31/592 ,  A61K31/593 ,  A61K31/675 ,  A61K31/7004 ,  A61K31/7008 ,  A61K31/708 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/714 ,  A61K33/00 ,  A61K33/04 ,  A61K33/06 ,  A61K33/14 ,  A61K33/18 ,  A61K33/22 ,  A61K33/24 ,  A61K33/242 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34 ,  A61K33/38 ,  A61N5/0603 ,  A61N5/0613 ,  A61Q11/00 ,  A61N5/062 ,  A61N5/067 ,  A61N5/0624 ,  A61N2005/063 ,  A61N2005/0606 ,  A61N2005/0659 ,  A61N2005/0663

摘要： A method of treating gum disease while healing the wound in the periodontium using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate the periodontium to regenerate and heal its wound when used with substrates, the method comprising: placing the tip of the laser inside the sulcus; penetrating the entire sulcus by moving the laser light circumferentially around the tooth vertically and horizontally throughout the sulcus with intermittent stops to control tissue temperature and placing substrates in the sulcus prior to blood clot formation; followed by RF treatment of the sulcus by placing the RF headpiece tips perpendicular to the sulcus to receive RF current which further penetrates the wound site.

公开(公告)号：US20230226097A1

公开(公告)日：2023-07-20

申请号：US18120189

申请日：2023-03-10

申请人： SOCIETE DES PRODUITS NESTLE S.A.

发明人： Gene Bowman ,  Julie Hudry-Labbe ,  Jeroen Antonius Johannes Schmitt ,  Corina Boschat ,  Claus Rieker

IPC分类号： A61K31/714 ,  A61P25/28 ,  A61K31/14 ,  A61K31/198 ,  A61K31/202 ,  A61K31/593 ,  G01N33/68 ,  G01N33/82 ,  A61K31/592

CPC分类号： A61K31/714 ,  A61P25/28 ,  A61K31/14 ,  A61K31/198 ,  A61K31/202 ,  A61K31/593 ,  G01N33/6896 ,  G01N33/82 ,  A61K31/592 ,  G01N2800/2821

摘要： A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

公开(公告)号：US11684797B2

公开(公告)日：2023-06-27

申请号：US17735034

申请日：2022-05-02

申请人： BIOREGENTECH, INC.

发明人： Margaret Kalmeta

IPC分类号： A61K33/42 ,  A61K38/39 ,  A61K33/00 ,  A61K33/38 ,  A61K33/34 ,  A61K33/24 ,  A61K33/26 ,  A61K8/41 ,  A61K31/07 ,  A61K8/24 ,  A61K8/44 ,  A61K8/20 ,  A61Q11/00 ,  A61K31/714 ,  A61K31/7004 ,  A61K31/122 ,  A61K33/14 ,  A61N5/06 ,  A61N1/40 ,  A61C1/00 ,  A61K31/198 ,  A61K8/368 ,  A61K31/592 ,  A61K8/65 ,  A61Q19/00 ,  A61K33/242 ,  A61K33/243 ,  A61N5/067

CPC分类号： A61N5/0603 ,  A61C1/0046 ,  A61K8/20 ,  A61K8/24 ,  A61K8/368 ,  A61K8/416 ,  A61K8/44 ,  A61K8/442 ,  A61K8/65 ,  A61K31/07 ,  A61K31/122 ,  A61K31/198 ,  A61K31/592 ,  A61K31/7004 ,  A61K31/714 ,  A61K33/00 ,  A61K33/14 ,  A61K33/24 ,  A61K33/242 ,  A61K33/243 ,  A61K33/26 ,  A61K33/34 ,  A61K33/38 ,  A61K33/42 ,  A61K38/39 ,  A61N1/40 ,  A61N5/062 ,  A61N5/0613 ,  A61N5/0624 ,  A61Q11/00 ,  A61Q19/00 ,  A61K2800/81 ,  A61N5/067 ,  A61N2005/063 ,  A61N2005/0606 ,  A61N2005/0651 ,  A61N2005/0659 ,  A61N2005/0663

摘要： A method of treating diseased tissue while healing the wound using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate epithelial regeneration when used with or without substrates. A method of treating diseased tissue using a laser light in the green wavelength range (520-570 nm) at a laser power of 0.001 W to 5 W. A method of treating diseased tissue using a laser light in the IR wavelength range (700-1400 nm) at a laser power of 0.001 W to 5 W.

公开(公告)号：US20220288018A1

公开(公告)日：2022-09-15

申请号：US17720720

申请日：2022-04-14

申请人： Pre-D Partners LLC

发明人： Robert Shorr

IPC分类号： A61K31/385 ,  A61K31/592 ,  A61K31/593 ,  A61K45/06 ,  C07K14/47

摘要： The disclosure provides thiol-containing alkyl fatty acid and vitamin D compound formulations for intra-venous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are useful for treating metabolic dysfunctions such as pre-diabetes, Metabolic Syndrome and diabetes. Also provided are methods of treatment comprising the daily administration of the disclosed thiol-containing alkyl fatty acid formulations alone or in combination with the disclosed vitamin D compound formulations.

公开(公告)号：US11439651B2

公开(公告)日：2022-09-13

申请号：US17374819

申请日：2021-07-13

申请人： CoFix-RX, LLC

发明人： Ravi Hedni ,  Karen Raehtz ,  Dennis G Kaiser ,  Andrew Krause

IPC分类号： A61K31/593 ,  A61K9/00 ,  A61K47/36 ,  A61K47/02 ,  A61K31/592 ,  A61K47/26

摘要： A nasal spray solution of the present invention includes a Povidone iodine solution; a Vitamin D liquid, Polysorbate 80 nf, Xylitol NF, water sterile, Sodium hydroxide 10% solution, and Polysaccharide 1% solution, wherein 1% solution further includes a gellan gum and a carrageenan, used as carriers to deliver liquids to cells of human and act as entrapment within a polymeric coating to block virus uptake into the cells, inactivate the virus, and protect a lining of an upper respiratory pathways against COVID-19 and SARS.

公开(公告)号：US20220125806A1

公开(公告)日：2022-04-28

申请号：US17570194

申请日：2022-01-06

申请人： EIRGEN PHARMA LTD.

发明人： Jay A. White ,  Samir P. Tabash ,  Sammy A. Agudoawu ,  Joel Z. Melnick

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K47/38 ,  A61K47/44

摘要： A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

公开(公告)号：US20220000995A1

公开(公告)日：2022-01-06

申请号：US17458018

申请日：2021-08-26

申请人： Diamyd Medical AB

发明人： Anders ESSEN-MÖLLER ,  Johnny LUDVIGSSON

IPC分类号： A61K39/00 ,  A61K9/00 ,  A61K45/06 ,  A61K31/192 ,  A61K31/197 ,  A61K31/592 ,  A61K31/593 ,  A61K38/19 ,  A61K38/43 ,  A61K38/28 ,  A61K38/17

摘要： The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, and to composition comprising i) at least one beta cell autoantigen, and at least one of iia) an IL-10 inducing compound selected from the group consisting of vitamin-D, vitamin-D analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve CD4+ T cells, such as a cyclooxygenase inhibitor, a CTLA-4 compound or a TNF alpha inhibitor. The invention also relates to pharmaceutical kits and to medical use of beta cell autoantigens.

公开(公告)号：US11090276B2

公开(公告)日：2021-08-17

申请号：US15308926

申请日：2015-05-05

申请人： BASF SE

发明人： Inger Reidun Aukrust ,  Helena M. Larsson ,  Thomas Rove

IPC分类号： A61K31/122 ,  A61K45/06 ,  A23P10/30 ,  A23P10/35 ,  A23L33/15 ,  A61K9/20 ,  A61K9/16 ,  A61K9/50 ,  A61K31/593 ,  A61K33/08 ,  A61K33/10 ,  A61K31/592 ,  A23K20/174 ,  A23K20/20 ,  A23L33/16 ,  A23L2/52 ,  A61K9/00

摘要： The invention relates to a composition comprising A) microcapsules comprising at least one fat-soluble active substance selected from a vitamin K compound or a provitamin or a prodrug of a vitamin K compound embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, and B) at least one dietary mineral; as well as uses and products comprising such compositions.